Intersect ENT

Intersect ENT is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The Company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
2003
Size (employees)
303 (est)
Intersect ENT was founded in 2003 and is headquartered in Menlo Park, US

Key People/Management at Intersect ENT

Lisa Earnhardt

Lisa Earnhardt

President & CEO
Monika De Martini

Monika De Martini

CFO
Robrt Binney

Robrt Binney

Vice President of Sales
Amy Wolbeck

Amy Wolbeck

Vice President, Regulatory Affairs and Quality
Susan P Stimson

Susan P Stimson

Vice President of Marketing
Rich Kaufman

Rich Kaufman

Senior Vice President and Chief Operating Officer

Intersect ENT Office Locations

Intersect ENT has an office in Menlo Park
Menlo Park, US (HQ)
1555 Adams Dr

Intersect ENT Financials and Metrics

Intersect ENT Financials

Intersect ENT's revenue was reported to be $78.7 m in FY, 2016
USD

Revenue (Q3, 2017)

22.3 m

Gross profit (Q3, 2017)

18.5 m

Gross profit margin (Q3, 2017), %

83%

Net income (Q3, 2017)

(4.3 m)

EBIT (Q3, 2017)

(4.6 m)

Market capitalization (13-Nov-2017)

837.1 m
Intersect ENT's current market capitalization is $837.1 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

38.6 m61.6 m78.7 m

Revenue growth, %

60%28%

Cost of goods sold

10.2 m12.3 m13 m

Gross profit

28.4 m49.3 m65.7 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

15.2 m14.2 m16.7 m19.3 m18.5 m20.5 m24 m22.3 m

Cost of goods sold

2.9 m2.9 m3.2 m3.1 m2.8 m2.9 m3.7 m3.8 m

Gross profit

12.3 m11.4 m13.5 m16.2 m15.7 m17.6 m20.3 m18.5 m

Gross profit Margin, %

81%80%81%84%85%86%85%83%
USDFY, 2014FY, 2015FY, 2016

Cash

13.4 m34.8 m9.9 m

Accounts Receivable

8.3 m11.5 m14.4 m

Inventories

951 k1.5 m1.3 m

Current Assets

60.3 m141.2 m125.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Accounts Receivable

11.7 m

Inventories

1.6 m

Accounts Payable

2.5 m
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (18.4 m)(26.6 m)(25.2 m)

    Depreciation and Amortization

    1.2 m

    Accounts Receivable

    (4.1 m)(3.1 m)(3 m)

    Inventories

    (541 k)(544 k)(1.7 m)
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (5.8 m)(9.7 m)(8.2 m)(6 m)(6.2 m)(6.7 m)(4.3 m)

    Accounts Receivable

    4.5 m4.9 m8 m8.8 m8.5 m9.5 m10 m10 m12.3 m12.3 m11.7 m

    Inventories

    2.8 m2.7 m2.8 m3.2 m3.7 m4.9 m5.9 m7.2 m7.1 m8 m1.6 m

    Accounts Payable

    2.7 m2.1 m2 m2.5 m3.2 m2.9 m2.6 m3.2 m2.3 m2.5 m2.5 m
      Show all financial metrics

      Intersect ENT Operating Metrics

      Intersect ENT's Patients Served was reported to be 150 k in FY, 2016
      FY, 2016

      Patients Served

      150 k

      Patents Issued

      77

      Facilities

      1

      Trademarks Pending

      35
      Show all operating metrics

      Intersect ENT Market Value History

      Intersect ENT's Web-traffic and Trends

      Intersect ENT Online and Social Media Presence

      Intersect ENT Company Life and Culture

      You may also be interested in